EXEL•benzinga•
Exelixis Stock Soars As Analysts Applaud Raised 2025 Guidance, Q1 Earnings Beat
Summary
Exelixis lifts 2025 revenue outlook after strong Q1 driven by Cabometyx sales surge and early traction in the neuroendocrine tumor market.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 14, 2025 by benzinga